To demonstrate our strategy for hilar bile duct cancer and to elucidate prognostic factors and the surgeon's role in longterm survival. Summary Background Data: Extended hemihepatectomy is recognized as a curative treatment of hilar bile duct cancer but is not always safe because of the risk of postoperative liver failure. A safe and beneficial strategy is required. Methods: Fifty-eight consecutive major hepatectomies for hilar bile duct cancer were reviewed retrospectively. Appropriate preoperative treatments, biliary drainage, and portal embolization were performed before major hepatectomies. The short-and long-term results of our strategy are presented and analyzed. Results: Biliary drainage and portal embolization were performed in 39 patients (67.2%) and 31 patients (53.4%), respectively. Major hepatectomies comprised 27 extended right and 22 extended left hemihepatectomies and 9 hepatoduodenopancreatectomies. Operative morbidity and mortality rates were 43% and 0%, respectively. There was no postoperative liver failure. The overall 5-year survival rate was 40%. Univariate analysis showed that residual tumor status, lymph node involvement, and perineural invasion were associated with patients' long-term survival. A surgical margin over 5 mm resulted in better long-term survival. The delay resulting from preoperative treatment was not detrimental to long-term survival. Multivariate analysis showed that lymph node involvement was the only prognostic factor. Conclusions: Our strategy, which includes preoperative biliary drainage and portal embolization, led to a reduction in the risks associated with major hepatectomy for hilar bile duct cancer, and resulted in zero mortality. Surgeons should aim at complete clearance of the tumor with an adequate surgical margin to ensure optimal long-term survival. (Ann Surg 2003;238: 73-83) H ilar bile duct cancer is known to be a slow-growing and late-metastasizing tumor, but its anatomic location and longitudinal extent along the bile duct have made curative resection difficult, resulting in low resectability, high mortality, and poor long-term survival. 1-5 Recently, major hepatectomy has been advocated for complete tumor clearance, and since then resectability and long-term survival rates have improved. 6 -17 However, because most patients with hilar bile duct cancer have obstructive jaundice, major hepatectomy is not always safe, contributing to high morbidity and mortality rates. 3,5,7,8,10 -18 Therefore, a safe and curative strategy is required for hilar bile duct cancer to reduce operative risk and improve long-term survival. We consider the following elements to be vital for such a strategy: a proper choice of surgical procedure, appropriate preoperative treatment, skillful surgical technique, and careful postoperative management. In this report, we retrospectively review the records of 58 consecutive major hepatectomies, we describe our strategy for curative resection for hilar bile duct cancer, and we discuss the short-and long-term results, paying attention to the risks and benefits of major hepatectomy.
PATIENTS AND METHODS

Patients
Between February 1989 and November 2001, surgical interventions with curative intent were performed on 93 of 131 consecutive patients who had tumors involving the hepatic hilum, and 87 patients underwent resection (resectability rate, 66.4%) by a single surgeon using the same strategy. Major hepatectomies, including extended right (ERH) or left hepatectomies (ELH), were performed in 78 of the 87 resections (89.7%). Limited resections were selected for the remaining 9 patients because of poor liver function, poor general condition, or limited tumor spread. This study comprises 58 cases of bile duct cancer originating from the hepatic hilum, in 40 men and 18 women, with a mean age of 66.3 years (range, 39 to 84 years). Intrahepatic cholangiocellular carcinoma (n ϭ 14) and cystadenocarcinoma (n ϭ 6) involving the hepatic hilum were excluded because the prognoses for these carcinomas are different from that for hilar bile duct cancer. Clinicopathological and interventional records for these 58 consecutive major hepatectomies were reviewed retrospectively.
Preoperative Investigations and Treatments
Preoperative treatment was performed according to the flow chart shown in Figure 1 . Resectability was assessed and the type of hepatectomy was selected, depending on the location and extent of the tumor as determined by ultrasonography and computed tomography. Patients with para-aortic lymph node metastasis or other distant metastases were not included as candidates for resectional surgery. The longitudinal extent of resected tumors along the bile duct were classified according to a modified Bismuth-Corlette classification as type I (n ϭ 9, 15.5%), type II (n ϭ 8, 13.8%), type IIIa (n ϭ 14, 24.1%), type IIIb (n ϭ 11, 19.0%), and type IV (n ϭ 16, 27.6%). 2, 19 If a patient showed evidence of jaundice or there were dilated bile ducts in the future remnant liver, biliary drainage (BD) was performed in principle only on the future remnant ( Fig. 1 ). When segmental cholangitis could not be controlled after hemihepatic biliary drainage, another BD tube was added to resolve the infection. Tumor extent along the bile duct was investigated by cholangiography via a BD route. If the tumor had spread diffusely into the intrapancreatic part of the common bile duct, pancreatoduodenectomy was per-formed simultaneously (hepatopancreatoduodenectomy, HPD). 20 After sufficient recovery of hepatic function, surgical interventions were scheduled. To avoid postoperative liver failure, portal embolization (PE) using gelatin sponge powder was carried out depending on liver function and the parenchymal liver volume to be resected, which was calculated by computed tomography (Fig. 1 ). [21] [22] [23] Details of this calculation have been described elsewhere. 23 In cases of HPD, PE was routinely performed. PE was performed after sufficient BD (serum bilirubin level Յ5 mg/dL). In principle, resectional surgery was performed when the serum bilirubin level had decreased to Յ2 mg/dL.
Surgical Procedure
After appropriate preoperative treatment, extended hemihepatectomy with resection of the extrahepatic bile duct was performed using previously described techniques. 16, 22, 24 Lymph nodes located in the hepatoduodenal ligament, behind the pancreatic head, along with the common hepatic artery, and at the right side of the root of the celiac artery, were dissected en bloc in so far as this was possible. ERH included resection of the right liver, the inferior part of the Couinaud's segment IV, and the entire caudate lobe. ELH included the left liver, the hilar part of the anterior segment, and most of the caudate lobe. The hepatic parenchyma was divided using Pringle's maneuver. 25 The biliary tract was reconstructed by bilioenterostomy using a Roux-en-Y loop, and internal stents were placed across the anastomosis. 26 In patients with PTBD, long stents were placed via the PTBD route, which were removed 3-6 weeks after operation. In cases of HPD, the complete external drainage of pancreatic juice followed by second-stage pancreato-jejunostomy was employed. [27] [28] [29] 
Classification of Resected Tumors
Surgical curability was defined by residual tumor status: R0 indicated no residual tumor (n ϭ 37, 63.8%), R1 indicated microscopic residual tumor (n ϭ 18, 31.0%), and R2 indicated macroscopic residual tumor (n ϭ 3, 5.2%). Patients classed as R0 (curative resection) were further divided into 2 groups: group A comprised those in whom the surgical free margin was more than 5 mm (n ϭ 13, 35.1%), whereas group B comprised those in whom the tumor was found within 5 mm from the cut surface but was not exposed (n ϭ 24, 64.9%). Patients were grouped according to the pTNM Pathologic Classification as stage I (n ϭ 2, 3.4%), stage II (n ϭ 11, 19.0%), stage III (n ϭ 7, 12.1%), or stage IV A (n ϭ 38, 65.6%). pT numbers were used to classify the depth of tumor invasion: pT1 indicated invasion into the ductal wall (n ϭ 2, 3.4%), pT2 indicated invasion into the perifibromuscular connective tissue (n ϭ 18, 31.0%), and pT3 indicated invasion into adjacent structures (n ϭ 38, 65.6%). Lymph node metastasis was classified into 3 groups: pN0 indicated no lymph node metastasis (n ϭ 28, 48.3%), pN1 indicated lymph node metastasis within the hepatoduodenal ligament (n ϭ 17, 29.3%), and pN2 indicated lymph node metastasis beyond the hepatoduodenal ligament (n ϭ 13, 22.4%). Histologic findings were classified by histopathological grading: G1 indicated well-differentiated adenocarcinoma (n ϭ 29, 50.0%), G2 indicated moderately differentiated adenocarcinoma (n ϭ 24, 41.4%), and G3 indicated poorly differentiated adenocarcinoma (n ϭ 5, 8.6%).
Postoperative Follow-Up
After discharge, the patients were followed up monthly or bimonthly with ultrasonographic examination and measurement of serum level of tumor makers, including carcinoembryonic antigen and carbohydrate antigenic determinant 19 -9. Computed tomography was performed every 6 months. When tumor recurrence was confirmed by these examinations, systemic chemotherapy was performed either intravenously or orally according to the general condition of the patient. Radiation therapy was applied in patients with bone metastasis.
Statistical Analysis
Figures are expressed as median values with the range in brackets, unless otherwise indicated. Patient survival was analyzed using the Kaplan-Meier method, and univariate analysis was performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model. A P value of Յ0.05 was considered statistically significant. Patient survival was measured in days from resectional surgery until death.
RESULTS
Preoperative Treatment
Thirty-nine patients underwent preoperative BD (67.2%, see Table 1 ). Percutaneous transhepatic BD (PTBD) was used for 25 patients, and endoscopic nasal BD (ENBD) for 14 patients. Hemihepatic BD of only the future remnant liver was performed in 19 patients and BD of the whole liver in 20 patients. The maximum serum total bilirubin level before BD in the 39 patients was 10.8 mg/dL (range, 1.3 to 29.8 mg/dL). Serum total bilirubin levels before PE (n ϭ 23) and major hepatectomy (n ϭ 39) were 1.7 mg/dL (range, 0.5 to 17.0 mg/dL) and 1.3 mg/dL (range, 0.4 to 3.2 mg/dL), respectively. In all but 1 patient, PE was performed with serum bilirubin levels under 5 mg/dL. In the remaining patient, PE was performed with a total bilirubin level of 17.0 mg/dL because of persistent jaundice after BD. Details of the clinical course following PE have been described elsewhere. 30 Cholangitis occurred in 12 of the 39 patients (30%); 11 cases (92%) occurred in the first 8 years of the study, and there was only a single case in the last 5 years. In the hemihepatic BD group, segmental cholangitis occurred in 5 of 19 patients, but only 2 of them needed insertion of additional drainage tubes to control the infection, whereas in the other 3 the cholangitis subsided when treated with antibiotics. The causes of cholangitis were repeated cholangiography in 5 patients (42%), tube occlusion in another 5 patients (42%), and hemihepatic ENBD in 2 patients (16%). Another complication, cutaneous seeding of the tumor at the site of tube insertion, occurred in 2 of 26 patients who underwent PTBD (7.6%). In these 2 patients, the tumors were far advanced (pT3, pN2: stage IV A) and were microscopically residual at the cut end of hepatic duct, and the patients died of multiple organ metastases within a year. PE was performed in 47 of the 131 patients, and major hepatectomy was performed in 40 patients (51.3% of all major hepatectomies). Nine of 40 patients were excluded from this study because the diagnoses were either cholangiocellular carcinoma or cystadenocarcinoma. Consequently, PE was performed in 31 of 58 major hepatectomies (53.4%) for hilar bile duct cancer, followed by 21 ERHs, 1 ELH, and 9 HPDs ( Table 1 ). The mean percentile volumes of future remnant liver before and after PE were 34.3% (SD, 6.1%) and 43.3% (SD, 6.6%), respectively, representing a hypertrophic rate of 127%. In the 7 patients with PE who did not undergo major hepatectomy, 3 underwent limited resections without major hepatectomy because of the localized tumor spread at laparotomy, 1 underwent exploratory laparotomy, 1 was treated with palliative procedure, and further treatment were not performed in the remaining two. In these patients, there were no serious complications associated with the remnantembolized lobe.
The durations of preoperative treatments are shown in Table 2 . Patients who underwent both BD and PE (n ϭ 23) waited 46 days (range, 14 to 86 days) before major hepatectomy, but these patients survived as long as the others (Table 3 ).
Surgical Treatment
Major hepatectomies in 58 patients comprised 27 ERHs, 21 ELHs, 9 HPDs, and 1 left trisectionectomy (Table  1) . Curative resection was performed in 37 of 58 patients (63.8%). Combined vascular resection was performed in 9 patients (15.5%). Blood loss was 850 mL (range, 420 to 3100 mL) and whole blood transfusion was only required in 7 patients (12%). Tumor extension to the intrapancreatic bile duct was pathologically confirmed on the resected specimens in all 9 patients with HPD; furthermore, there was pancreatic invasion in 5 of them.
Operative Morbidity and Mortality
Overall morbidity and mortality rates were 43% and 0%, respectively. There was no postoperative liver failure: maximum serum total bilirubin levels after major hepatectomy were 1.4 mg/dL (range, 0.7 to 4.7 mg/dL) in patients without jaundice and 2.2 mg/dL (range, 0.8 to 9.3 mg/dL) in the BD group. Postoperative complications comprised 6 cases of cholangitis, 4 intra-abdominal abscesses, 4 cases of bile leakage, 3 cases of bleeding, 2 cases of pancreatic juice leakage, 1 case of pancreatitis, and 1 case of jejunal necrosis. Surgical intervention was needed in 4 patients for bleeding, intra-abdominal abscesses, bile leakage, or jejunal necrosis. All patients recovered well and were discharged from the hospital.
Survival According to Type of Surgery
Overall survival rates of the 58 patients who underwent major hepatectomy were 90.8% after 1 year, 54.8% after 3 years, and 40.0% after 5 years. Residual tumor status significantly influenced patients' long-term survival: 5-year survival rates after R0, R1, and R2 resections were 46.1%, 34.7%, and 0%, respectively (P Ͻ 0.001, Table 3 ), although the survivals after R0 and R1 were not significantly different. Figure 2 shows that among patients who had curative resections, a surgical margin of over 5 mm (group A) resulted in significantly better long-term survival than 1 of less than 5 mm (P ϭ 0.036), whereas there was no difference between the survival after R0 resection with narrow margin (Ͻ5 mm, group B) and that after R1. The type of hepatectomy and combined vascular resection did not influence patients' longterm survival ( Table 3) . Figure 3 shows that lymph node involvement had a strong influence on patients' long-term survival. The 5-year survival rate was 66.6% in pN0 patients, 22.5% in pN1, and 9.6% in pN2. Despite radical lymph node dissection, patients with lymph node metastasis beyond the hepatoduodenal ligament had a poor prognosis. Five patients without perineural invasion all survived well ( Table 3 ). The absence of perineural invasion was associated with a better prognosis. In contrast, neither tumor stage nor depth of invasion influenced patients' long-term survival ( Table 3 ). Even if the tumor invaded adjacent structures (pT3), the 5-year survival rate was 38.8%, improving to 53.4% in patients who had curative resections. II  11  8  40  50  III  7  4  35  24  IV  38  20  37  47  Residual tumor status  Ͻ0.001  R0  37  19  39  50  R1  18  10  42  47  R2  3  3  11  10  T factor  0.364  pT1  2  0  70  NA  pT2  18  12  37  39  pT3  38  20  37  47  N factor  Ͻ0.001  pN1  28  10  48  80  pN2  17  11  32  24  pN3  13  11  24 15 (Table continues) Annals Table 3 shows the results of univariate analysis of 16 clinicopathological parameters. Three significant parameters associated with patients' long-term survival were revealed: residual tumor stage (P Ͻ 0.001), lymph node involvement (P Ͻ 0.001), and perineural invasion (P ϭ 0.020). Lymph node involvement was the only significant prognostic factor in a multivariate analysis using parameters that had had low P values in the univariate analysis: residual tumor stage, lymph node involvement, and serum CEA level (Table 4 ).
Survival According to Tumor Condition
Because only 5 patients did not show perineural invasion and there were no death events in this subgroup, perineural invasion could not be included in the model.
DISCUSSION
In this study, we have demonstrated that resectional surgery for hilar bile duct cancer using our strategy of extended hemihepatectomy is low-risk and can provide good long-term survival. Although long-term results for resectional surgery for hilar bile duct cancer have been improving over FIGURE 2. Patient survival rate according to curability and surgical margin. In the R0 patients, the surgical margin was over 5 mm in group A, whereas the tumor was detected within 5 mm from cut surface, but not exposed, in group B. In these 4 groups, 5-year survival rates showed significant difference as a whole (P Ͻ 0.001). Five-year survival rates in groups A and B were also significantly different (group A: 81.8%; group B: 27.4%; P ϭ 0.036), whereas there was no difference between group B of R0 and R1. the last 10 years, there have been no studies reporting predominantly major hepatectomies with zero mortality. We performed extended hemihepatectomies in 58 patients over a period of 13 years and have demonstrated the safety and benefits of our strategy (no mortality and a 5-year survival rate of 40.0%). To our knowledge, these are the best results of any study of over 50 major hepatectomies ( Table 5 ). Our resectability rate of 66.4% is also high compared with previous reports. 9 It must be taken into consideration that extended hemihepatectomy can cause serious complications, and liver failure is a great concern in major hepatectomy for hilar bile duct cancer. 7, 13, 16, 20 We attach great importance to preoperative BD and PE, and to the reduction of intraoperative blood loss, to prevent postoperative liver failure following major hepatectomy.
Most patients with hilar bile duct cancer show liver dysfunction caused by obstructive jaundice, which is a risk factor in major hepatectomy. 31, 32 We performed preoperative BD according to our criteria shown in Figure 1 , and surgical interventions were performed after recovery of hepatic function, which took about 4 weeks. Although 67% of our series showed signs of obstructive jaundice, liver failure was not encountered after major hepatectomy. This result indicates that preoperative BD is effective in patients undergoing aggressive treatment of hilar bile duct cancer. However, the short-term effectiveness of BD has been controversial in previous comparative studies. [33] [34] [35] [36] We think this a result of inadequate BD and a low rate of major hepatectomy. In these studies, hepatic functional recovery was not sufficient because BD was only performed for 10 to 14 days and surgical interventions were performed at a total bilirubin value of about 10 mg/dL. 33, 34 Furthermore, resectional surgery was performed in only 10% of cases, while major hepatectomies comprise 89.7% of the current series. Cherqui et al reported 20 major liver resections for biliary cancer in jaundiced patients without BD with just 1 case of liver failure (5%); the patient later died. 37 Although they showed no significant differences for mortality and liver failure between jaundiced and nonjaundiced patients, our strategy is also justified by zero postoperative liver failure and mortality rates for the consecutive 58 major hepatectomies. When the right and left hepatic ducts have no communication at the hepatic hilum, we use hemihepatic BD, which is enough for recovery from obstructive jaundice and is better than BD of the whole liver for the preservation of liver function in the future remnant and compensatory hypertrophy of the lobe to be drained. 24, 38, 39 Although some authors have pointed out the risk of segmental cholangitis following hemihepatic BD, 13, 40 we had only 2 patients (10%) who needed the insertion of additional BD tubes to control infection.
A drawback with using preoperative BD is cholangitis. However, the common causes of infection are iatrogenic and avoidable, and the rate of cholangitis has dramatically decreased in the last 5 years because we have taken into account the following. First, in 42% of patients with cholangitis, it was related to repeated cholangiography. Therefore, to avoid cholangitis, preoperative cholangiograpy should be performed only at the time of insertion of the tube and on the evening before operation. This still gives adequate information for extended hemihepatectomy. Care must be taken not to put pressure on the biliary trees and not to visualize the bile duct of the undrained side, the side to be resected, to avoid pushing contaminated bile into the drained lobe. Second, the endoscopic route should not be selected if there is an interruption of communication between the right and left hepatic ducts, since cholangitis occurred in the undrained side of the livers of 2 of 4 patients who underwent hemihepatic ENBD. Additionally, the amount of drained bile should be carefully checked and cultured. Cholangitis may also result from occlusion of the drainage tube, but this can be resolved by changing the tube. Our results show that the risk of cholangitis can be reduced through proper and careful treatment, and that other dismal complications can also be avoided.
Other hepatectomy procedures, such as segmental liver resection and hilar liver resection, are the alternatives for reducing the volume of resected liver and increasing safety. 13, 15 However, these procedures are more complicated and take more time with more blood loss than extended hemihepatectomy. Furthermore, these procedures are indicated in only 10 to 15% of resected cases, and more interventional investigations are required to ascertain precisely the spread of the tumor. 13, 15 Further investigations, including whole liver cholangiography and percutaneous transhepatic cholangioscopy (PTCS), have clinical disadvantages. To visualize all the branches of the intrahepatic bile duct, more pressure is required, and thus more BD tubes are needed to treat segmental or sectional cholangitis. 41 The risk of cholangitis due to tube occlusion increases with an increasing number of BD tubes. In PTCS, biliary tracts have to be dilated gradually to allow introduction of the tube, causing a reduction in the portal flow of the segment. Tract seeding associated with the PTBD tube is also a disadvantage with preoperative BD, 41, 42 and multiple BD and PTCS may increase the risk. The risk of tumor seeding is minimal in our strategy because the minimum number of BD tubes is used and PTCS is not required. Although there were 2 cases of cutaneous seeding in the current series, it did not affect their prognoses because the tumors were already far-advanced (pT3, pN2) and the resections were noncurative.
Recent studies have described the safety and benefits of using PE. [21] [22] [23] [24] 43, 44 In our series, PE was performed in 31 of 58 patients and effectively induced hypertrophy of the future remnant liver. This result supports our indication criteria and procedure for PE. PE was not indicated in 6 patients who underwent ERH, whose tumors were all type IIIa and had infiltrated the hepatic parenchyma. Their right livers were already atrophic because of reduced portal flow. However, not all the patient with PE underwent major hepatectomy. We used gelatin sponge powder as an embolizing material, which induces hepatic parenchymal atrophy without major inflammatory or necrotic reaction. 43 In this series, there were also no serious complications associated with remnant embolized lobe in the 7 patients with PE who did not undergo major hepatectomy.
Although preoperative treatments delayed resectional surgery, our results indicate that delayed surgical intervention as a result of preoperative treatment is not detrimental to long-term survival. It takes over 4 weeks to resolve jaundice, 38, 45 and after PE it took an additional 2 weeks. Patients who underwent both BD and PE and who therefore had the longest preoperative treatment, survived as long as others who underwent only 1 or no preoperative treatment. Some authors have recommended immediate radical operation because of the risk of cholangitis and tumor seeding, but they also reported postoperative mortality and worse long-term survival. 11, 36 Cholangitis and tumor seeding are not serious problems in our strategy, as we have already mentioned.
To minimize the risk of postoperative liver failure, reduction of blood loss is also an important factor. 46 In our department, more than a hundred hepatectomies are performed each year without mortality and with low morbidity rates, even in patients with impaired livers. 47, 48 Such an established surgical technique for hepatectomy itself may be essential in the treatment of hilar bile duct cancer.
Bleeding and intraabdominal infection are other lifethreatening complications occurring after major hepatectomy for hilar bile duct carcinoma. 16 These complications are attributable to the surgery and can be reduced through meticulous procedures and managed by immediate response. 47, 48 Our morbidity rate was 43%, but most cases were minor complications: only 4 patients needed surgical intervention, and the complications were well controlled.
Univariate analysis showed that residual tumor stage, perineural invasion, and lymph node involvement were significant factors associated with patients' long-term survival. Some reports have suggested that invasion of the tumor into adjacent structures or vessels, treated by combined vascular resection and reconstruction, are factors associated with a poor prognosis. 9, 11, 14 These factors, however, did not influence our patients' long-term survival when the tumor could be completely removed by en bloc resection. This result justifies radical resection by extended hemihepatectomy for hilar bile duct cancer. Perineural invasion is another route by which the tumor may spread and has been suggested as a prognostic factor. 49 In the current series, the absence of perineural invasion was also associated with a better prognosis. However, there were only 5 patients without perineural invasion, and although all are alive, the small size of the group without death events means that the importance of perineural invasion cannot be determined statistically.
Lymph node involvement is a strong and the only predictive factor revealed by multivariate analysis, and reflects the progression of the cancer, as has previously been reported. 15, 16, 50 If lymph node metastasis had spread beyond the hepatoduodenal ligament (N2), long-term survival was not expected even if radical lymph node dissection was performed. 50 In the present series, only 1 of 13 patients with N2 survived over 5 years.
A tumor-free margin is usually of great concern in resectional surgery. Although the survival after R0 resection was not significantly different from that after R1 in this series, a surgical margin over 5 mm provided a significantly better survival and was considered to be sufficient, as has previously been reported. 51 On the other hand, the survival after R0 with narrow margin (Ͻ5 mm, group B) was nearly the same as after R1. The surgical margin has 2 aspects in hilar bile duct cancer: a cut ends of the bile ducts, and a dissected surface. Tumor was detected close to the dissected surface in all 24 patients with R0 group B, whereas the surgical margin in the longitudinal direction along the bile duct was wide in 13 of them. It is speculated that the survival after R0 is not different from that after R1 when the tumor was detected close to the dissected surface. Because the number of the patients and the death events was not enough to analyze many subgroups in this study, it may require more cases to prove this speculation.
Because both lymph node status and perineural invasion are tumor-related factors and are determined at presentation, we suggest that the surgeon's role in a patient's long-term survival is the complete removal of the tumor, with an adequate surgical margin to minimize risks.
Although we have introduced our safe and beneficial strategy for the hilar bile duct cancer and showed the result, this report is a retrospective study. Strictly speaking, to prove the effect of preoperative treatment, randomized controlled trial may be required.
CONCLUSIONS
Our strategy, including preoperative biliary drainage and portal embolization, may resolves the questions surrounding the benefits and the risks associated with major hepatectomy as a treatment of hilar bile duct cancer, by achieving zero mortality. A good long-term survival rate shows that the delay due to preoperative treatment is not detrimental to long-term survival. Although lymph node involvement is the strongest prognostic factor, surgeons should aim at complete clearance of the tumor with an adequate surgical margin for better long-term survival.
